Obstetric Service, Department Woman-Mother-Child, Lausanne University Hospital, Rue du Bugnon 21, CH-1011, Lausanne, Switzerland.
Institute of Higher Education and Research in Healthcare (IUFRS), University of Lausanne, Lausanne, Switzerland.
Cardiovasc Diabetol. 2023 Oct 27;22(1):291. doi: 10.1186/s12933-023-02034-9.
Women with gestational diabetes mellitus (GDM) have higher insulin resistance and/or reduced secretion, an increased risk of future diabetes and cardiovascular disease, which may be due to a pathological activation of the innate immune system. C-reactive protein (CRP) is induced by inflammatory cytokines and reflects innate immune activity. We investigated the prospective associations between CRP during the perinatal period with adverse metabolic outcomes at 1 year postpartum in women with previous GDM.
We analyzed data from the MySweetheart trial that included 211 women with GDM at 28-32 weeks gestational age (GA). CRP was measured during pregnancy at 28-32 weeks GA, at 6-8 weeks and at 1 year postpartum. Metabolic outcomes at 1 year postpartum included weight, total and central body fat, measures of insulin resistance and secretion and presence of the metabolic syndrome (MetS). A 75 g oral glucose tolerance test was performed to measure glucose and insulin values every 30 min over 2 h to calculate indices of insulin resistance (MATSUDA, HOMA-IR) and of absolute (AUC, HOMA-B) and insulin resistance-adjusted insulin secretion (ISSI-2).
CRP during pregnancy and at 6-8 weeks postpartum predicted increased weight, body fat and visceral adipose tissue (VAT), insulin resistance (higher HOMA-IR, lower MATSUDA), absolute insulin secretion (HOMA-B, AUC), a reduced adjusted insulin secretion (ISSI-2) and a higher prevalence of the MetS at 1 year postpartum (all p ≤ 0.036). These relationships particularly those concerning CRP during pregnancy, were independent of weight ( for VAT, insulin resistance and secretion indices, MetS; all p ≤ 0.032) and of body fat ( for VAT, MATSUDA, MetS; all p ≤ 0.038). CONCLUSION: CRP during pregnancy and in the early postpartum predicted an adverse cardio-metabolic profile in women with prior GDM at 1 year postpartum independent of weight. The prospective association of CRP with increased insulin resistance and reduced adjusted insulin secretion hint to the role of inflammation in the development of impaired metabolism after GDM and could be used as an early marker for risk stratification.
患有妊娠糖尿病(GDM)的女性胰岛素抵抗和/或分泌减少,未来发生糖尿病和心血管疾病的风险增加,这可能是由于先天免疫系统的病理性激活。C 反应蛋白(CRP)由炎症细胞因子诱导,反映先天免疫活性。我们研究了妊娠期间 CRP 与先前患有 GDM 的女性产后 1 年不良代谢结局之间的前瞻性关联。
我们分析了 MySweetheart 试验的数据,该试验纳入了 211 名 28-32 孕周的 GDM 女性。在妊娠 28-32 周、6-8 周和产后 1 年时测量 CRP。产后 1 年的代谢结局包括体重、总脂肪和中心脂肪、胰岛素抵抗和分泌的测量以及代谢综合征(MetS)的存在。进行 75g 口服葡萄糖耐量试验,以 30 分钟为间隔测量 2 小时内的血糖和胰岛素值,以计算胰岛素抵抗指数(MATSUDA、HOMA-IR)和绝对胰岛素分泌量(AUC、HOMA-B)和胰岛素抵抗调整后的胰岛素分泌量(ISSI-2)。
妊娠期间和产后 6-8 周的 CRP 预测体重、体脂和内脏脂肪组织(VAT)增加、胰岛素抵抗(HOMA-IR 更高,MATSUDA 更低)、绝对胰岛素分泌(HOMA-B、AUC)、调整后的胰岛素分泌减少(ISSI-2)以及产后 1 年代谢综合征的患病率增加(所有 p 值均≤0.036)。这些关系,尤其是妊娠期间 CRP 与产后 1 年的 VAT、胰岛素抵抗和分泌指数、代谢综合征(所有 p 值均≤0.032),以及体脂(所有 p 值均≤0.038)的关系,是独立的。
妊娠期间和产后早期的 CRP 预测了先前患有 GDM 的女性产后 1 年时不良的心血管代谢特征,与体重无关。CRP 与胰岛素抵抗增加和调整后胰岛素分泌减少的前瞻性关联提示炎症在 GDM 后代谢受损的发展中的作用,并可作为风险分层的早期标志物。